Tectonic Therapeutic, Inc. (TECX)
NASDAQ: TECX · Real-Time Price · USD
29.54
-1.30 (-4.20%)
Feb 21, 2025, 4:00 PM EST - Market closed
Tectonic Therapeutic Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
44
Market Cap
435.79M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2014 | 137.88K | 2.88K | 2.13% |
| Dec 31, 2013 | 135.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
TECX News
- 17 days ago - Tectonic: Expansion Of TX45 Candidate Possible After Positive Interim Data - Seeking Alpha
- 19 days ago - Tectonic Announces $185 Million Private Placement - GlobeNewsWire
- 23 days ago - Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF - GlobeNewsWire
- 6 weeks ago - Tectonic Therapeutic: Protein Engineering Platform For GPCRs - Seeking Alpha
- 2 months ago - Tectonic Therapeutic to Host KOL Event on the Unmet Need in Group 2 PH-HFpEF and TX45 as a Potential Treatment on Thursday, December 12, 2024 - GlobeNewsWire
- 3 months ago - Tectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare Conference - GlobeNewsWire
- 3 months ago - Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein - GlobeNewsWire
- 4 months ago - Tectonic Therapeutic to Present Phase 1a Data at AHA 2024 - GlobeNewsWire